Quality Comes First

          

APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

Acquisition & Collaboration with Strategic Partners

Acquisition & Collaboration with Strategic Partners

Discover our recent acquisitions and collaborations.

We acquired the full rights in China for Cialis (tadalafil), an established erectile dysfunction treatment.

We acquired the Australia and New Zealand rights for Crestor (rosuvastatin), one of the most prescribed cholesterol drugs in the world.

Smyraf (peficitinib) is an innovative JAK inhibitor indicated for rheumatoid arthritis, in-licensed for Taiwan.

Dermatix Wound Care is an intelligent wound-healing hydrogel available in Indonesia, Malaysia, Thailand and Vietnam.

Monofer (ferric derisomaltose) is a clinically-developed, high-dose IV iron indicated for the treatment of iron deficiency, available in Australia.

Contact Us

We actively seek partners who share our commitment to addressing unmet needs and shaping a better future for patients.